---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-039425"
form_type: "8-K"
ticker: "LXEO"
cik: "0001907108"
company_name: "Lexeo Therapeutics, Inc."
filed_at: "2026-02-05T23:59:59+00:00"
generated_at: "2026-05-16T04:33:19.752723+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# LXEO Head of Research Dr. Adler departs; transition agreement through July 31, 2026

## Summary
- Dr. Adler stepped down as Head of Research effective February 1, 2026; will provide advisory services through July 31, 2026 or earlier termination.
- Under transition agreement, Dr. Adler will receive up to $62,500 in monthly installments; service-vesting equity continues to vest during transition period.
- Option exercise period extended to six months after transition end; additional $1,000 lump sum possible upon execution of supplemental release.
- Transition agreement includes customary release of claims, non-disparagement, and cooperation provisions.

## SEC filing metadata
- accession: 0001193125-26-039425
- form_type: 8-K
- ticker: LXEO
- cik: 0001907108
- company_name: Lexeo Therapeutics, Inc.
- filed_at: 2026-02-05T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1907108/000119312526039425/0001193125-26-039425-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1907108/000119312526039425/lxeo-20260130.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-039425
- JSON: https://secwatch.observer/filing/0001193125-26-039425.json
- Plain text: https://secwatch.observer/filing/0001193125-26-039425.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.